Lonza Signs Manufacturing Deal with U.S. Pharma Firm

Lonza says it has signed an agreement with Alnara Pharmaceuticals (Cambridge, MA), a company that develops and commercializes protein therapeutics for the treatment of metabolic diseases, to manufacture Alnara’s lead product liprotamase - an oral, pancreatic enzyme replacement therapy (PERT) for patients with pancreatic insufficiency. Lonza will provide microbial fermentation, process optimization, technical and regulatory support, under the terms of the deal, and all related production will be conducted in Lonza’s FDA registered facility at...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers